Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.61 |
| ▸ | TDO2 | P48775 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310627 | 1.00 | IDO1 (0.61) | IDO1TDO2ALDH1A1LMNACREBBP | |
| Hydrochloric Acid SCHEMBL9293017 | 0.99 | IDO1 (0.60) | IDO1TDO2ALDH1A1LMNACREBBP | |
| SCHEMBL30310617 | 0.85 | IDO1 (0.46) | IDO1TDO2ALDH1A1LMNACREBBP | |
| SCHEMBL23824559 | 0.85 | IDO1 (0.46) | IDO1TDO2ALDH1A1LMNACREBBP | |
| SCHEMBL24863624 | 0.81 | ALDH1A1 (0.47) | IDO1TDO2ALDH1A1LMNACREBBP | |
| SCHEMBL247406 | 0.79 | IDO1 (0.55) | IDO1TDO2TACR1ALPIPKM | |
| SCHEMBL247407 | 0.79 | IDO1 (0.55) | IDO1TDO2TACR1ALPIPKM | |
| SCHEMBL9766028 | 0.79 | ALDH1A1 (0.60) | IDO1TDO2ALDH1A1LMNACREBBP | |
| SCHEMBL9314057 | 0.76 | IDO1 (0.43) | IDO1TDO2 | |
| SCHEMBL29960617 | 0.76 | ALDH1A1 (0.53) | IDO1ALDH1A1LMNACREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2024-08-15 | — | — | US | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20220324844-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-10-13 | — | — | US | disclosed |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | IDO1 1609/4885TDO2 2112/4885ALDH1A1 3293/4885 |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | IDO1 1937/4885TDO2 1740/4885ALDH1A1 1798/4885 |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | IDO1 1937/4885TDO2 1740/4885ALDH1A1 1798/4885 |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | IDO1 1633/4885TDO2 2237/4885ALDH1A1 2252/4885 |
| US-11124497-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | IDO1 1651/4885TDO2 2431/4885ALDH1A1 1326/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | IDO1 1633/4885TDO2 2237/4885ALDH1A1 2252/4885 |
| US-11174231-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | IDO1 1633/4885TDO2 2237/4885ALDH1A1 2252/4885 |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | IDO1 1937/4885TDO2 1740/4885ALDH1A1 1798/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | IDO1 1937/4885TDO2 1740/4885ALDH1A1 1798/4885 |
| US-20220324844-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | IDO1 1937/4885TDO2 1740/4885ALDH1A1 1798/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | IDO1 1633/4885TDO2 2237/4885ALDH1A1 2252/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | IDO1 1859/4885TDO2 1845/4885ALDH1A1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.